A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
← catalyst calendarNCT07007793 · readout in 358 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
250estimated
Sites
89
Countries
Australia, Canada, China +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-07 | actual | When the study began enrolling |
| Primary completion | 2027-08-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Hyperaldosteronism
Interventions
- Drug: Baxdrostat — also filed as CIN-107
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in seated Systolic Blood Pressure (SBP) at Week 8
measured At week 8
Achieving normalization of the Renin Angiotensin Aldosterone System (RAAS) at week 8.
measured At week 8
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed